UK Patient Derived Xenografts/PDX Models Market (2025-2030)
The UK Patient Derived Xenografts/PDX Models Market was valued at $19.8 Million in 2025 and projected to reach to $31 Million by 2030, representing a compound annual growth rate of 9.3%. The UK PDX Models Market is positioned for steady growth at a 9.3% CAGR through 2030, supported by the country's strong pharmaceutical research infrastructure and increasing investment in oncology research.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
UK Patient Derived Xenografts/PDX Models Market Trends and Insights
- The UK market benefits from strong pharmaceutical research infrastructure, advanced oncology research capabilities, and increasing adoption of personalized medicine approaches.
- UK-based biotech firms and academic institutions are leveraging PDX models to accelerate drug development and improve clinical trial outcomes. Driving growth in the UK market are rising investments in cancer research, regulatory support for precision medicine, and collaboration between UK research centers and global pharmaceutical companies.
- The UK's established position in life sciences innovation and access to specialized research facilities position it as a key hub for PDX model development.
- Between 2025 and 2030, the UK market will benefit from expanded funding for translational research and growing demand for patient-derived models in preclinical testing. The UK PDX market reflects broader European trends toward advanced in vivo modeling, with UK institutions leading adoption among European markets.
- Continued expansion is expected as UK pharmaceutical and biotech sectors increasingly integrate PDX models into their drug discovery pipelines..
Key Market Statistics
- CAGR (2025-2030) 9.3% CAGR
- Market Size, 2025 ~USD 19.8 Million
- Forecast, 2030 ~USD 31 Million
- Country UK
UK Patient Derived Xenografts/PDX Models Market Overview
Market Valuation :
The UK PDX Models Market is valued at $19.8 million in 2025, with projected growth to $31.0 million by 2030, driven by robust pharmaceutical R&D investments and oncology research expansion.
Research Infrastructure :
The UK benefits from world-class pharmaceutical research institutions, including leading cancer research centers and biotech hubs that actively integrate PDX models into drug development pipelines.
Personalized Medicine Adoption :
Increasing adoption of precision oncology and personalized treatment approaches across UK healthcare systems is accelerating demand for patient-derived xenograft models in clinical decision-making.
Biotech Ecosystem :
UK-based biotech firms and academic institutions are leveraging PDX technology for translational research, creating a competitive advantage in early-stage drug discovery and development.
UK Patient Derived Xenografts/PDX Models Market Dynamics
- The UK's commitment to precision medicine and personalized cancer treatment is driving adoption of PDX models among leading research institutions and biotech companies.
- Regulatory support for advanced research methodologies and collaboration between academia and industry further strengthen market expansion.
- However, growth remains slightly below the global 12.5% CAGR, reflecting the mature nature of the UK research market and established alternative methodologies.
- Strategic partnerships and funding initiatives will continue to enhance PDX model utilization in drug development and clinical applications..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- The UK PDX Models Market is valued at $19.8 million in 2025 and will reach $31.0 million by 2030, growing at 9.3% CAGR.
- UK research institutions and biotech companies are driving adoption of PDX models for oncology drug development and personalized medicine.
- Strong regulatory support and increased cancer research funding in the UK are accelerating market expansion through 2030.
- The UK represents a leading European hub for PDX model innovation, attracting global pharmaceutical partnerships and investment.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
UK Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 4.39 | 4.79 | 5.25 | 5.76 | 6.28 | 6.82 | 7.41 | 8.04 | 8.9 |
| CROS & CDMOS | 2.86 | 3.11 | 3.39 | 3.7 | 4.02 | 4.35 | 4.71 | 5.08 | 8.4 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 9.19 | 10.12 | 11.18 | 12.36 | 13.59 | 14.9 | 16.32 | 17.86 | 9.8 |
| TOTAL | 16.43 | 18.02 | 19.82 | 21.82 | 23.89 | 26.07 | 28.44 | 30.98 | 9.3 |
Target Audience
- UK Pharmaceutical Companies : Need market data to assess PDX adoption trends, competitive positioning, and R&D investment opportunities within the UK oncology research and drug development landscape.
- Biotech Firms & CROs : Require UK-specific market insights to identify growth opportunities, establish partnerships with research institutions, and develop PDX-based service offerings for clinical trials.
- Research Institutions & Universities : Seek market intelligence to justify PDX model investments, secure funding, and understand adoption trends among peer institutions and industry collaborators in the UK.
- Healthcare Investors & VCs : Need comprehensive UK market analysis to evaluate investment potential in PDX technology companies, biotech startups, and research-focused ventures within the British healthcare sector.
- Medical Device & Service Providers : Require UK market data to develop targeted solutions, identify customer segments, and understand demand drivers for PDX-related products and services in the British market.
Key Companies in the UK Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Reasons to Buy this Report
- UK-Specific Market Intelligence : Gain detailed insights into the UK PDX market dynamics, including valuation trends, growth drivers, and competitive landscape specific to British biotech and pharmaceutical sectors.
- Investment Decision Support : Make informed investment decisions with accurate market sizing, CAGR projections, and forecasts tailored to the UK market through 2030, enabling strategic capital allocation.
- Regulatory & Infrastructure Insights : Understand UK-specific regulatory environment, research infrastructure advantages, and institutional adoption patterns that influence PDX model implementation and commercialization strategies.
- Competitive Positioning : Identify key UK-based players, research institutions, and biotech firms leveraging PDX technology, enabling competitive benchmarking and partnership opportunities within the British market.
- Growth Opportunity Assessment : Evaluate emerging opportunities in UK personalized medicine adoption, precision oncology expansion, and academic-industry collaborations driving PDX model demand and market expansion.
Frequently asked questions
What is the current size of the UK PDX Models Market?
The UK Patient Derived Xenografts Models Market is valued at $19.8 million in 2025 and is expected to grow to $31.0 million by 2030.
What is the growth rate of the UK PDX market?
The UK PDX Models Market is growing at a compound annual growth rate (CAGR) of 9.3% from 2025 to 2030.
Which sectors are driving PDX adoption in the UK?
UK pharmaceutical companies, biotech firms, and academic research institutions are the primary drivers of PDX model adoption for oncology research and drug development.
Why is the UK a key market for PDX models?
The UK's advanced research infrastructure, strong life sciences ecosystem, regulatory support for precision medicine, and established oncology research capabilities make it a leading PDX market in Europe.
What factors will support UK PDX market growth through 2030?
Increased cancer research funding, regulatory backing for personalized medicine, international pharmaceutical partnerships, and growing demand for preclinical testing models will drive UK market expansion.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- Canada Patient Derived Xenografts/PDX Models Market
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- China Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- India Patient Derived Xenografts/PDX Models Market
- Australia Patient Derived Xenografts/PDX Models Market
- South Korea Patient Derived Xenografts/PDX Models Market
- Brazil Patient Derived Xenografts/PDX Models Market
- Mexico Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Europe Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Rest Of Latin America Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report